Cargando…
Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
A successful cancer vaccine needs to overcome the effects of immune-suppressor cells such as Treg lymphocytes, suppressive cytokine-secreting Tr1 cells, and myeloid-derived suppressor cells (MDSCs), while enhancing tumor-specific immune responses. Given the relative poor efficacy associated with cur...
Autores principales: | Karkada, Mohan, Quinton, Tara, Blackman, Rachelle, Mansour, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606802/ https://www.ncbi.nlm.nih.gov/pubmed/23533812 http://dx.doi.org/10.1155/2013/753427 |
Ejemplares similares
-
Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera
por: Akinlaja, Olukayode, et al.
Publicado: (2016) -
Diabetes insipidus in a patient with PCOS treated with Depo-Provera
por: Martinez, Amanda I, et al.
Publicado: (2022) -
Plasma biomarker analysis of ovarian cancer patients undergoing immunotherapy with therapeutic cancer vaccine DPX-Survivac
por: Karkada, Mohan, et al.
Publicado: (2015) -
Conjunctival Necrosis due to Subconjunctival Methylprednisolone (Depo-Medrol™) Acetate Injection
por: van Zyl, L. M., et al.
Publicado: (2010) -
Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)